Gabapentin
Product Images NDC 68071-2308

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-2308). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2308 9)

Gabapentin 300mg capsules by NuCare Pharmaceuticals, Inc. This label is for a 90-count prescription bottle. The capsule is described as oblong, opaque yellow with 'SG' on the cap and '180' on the body. The label includes storage instructions to keep between 59-86°F and a warning to keep out of reach of children.*

FDA Label Image

Figure 1 (Image 01)

A line graph depicting the mean pain score over 8 weeks for two groups: placebo and Gabapentin 3600 mg/day. The x-axis represents time in weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a greater decrease in mean pain scores compared to placebo over time.*

FDA Label Image

Figure 2 (Image 02)

A line graph showing mean pain scores over 7 weeks for placebo and two dosages of gabapentin (1800 mg/day and 2400 mg/day). The X-axis represents weeks divided into a 3-week dose titration period and a 4-week fixed dose period, while the Y-axis shows the mean pain score from 0 to 10. Scores decrease over time for both gabapentin doses compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) doses across two studies. The vertical axis shows percentage responders from 0% to 100%. Study 1 shows 12% response for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated by ** and *** for p-values less than 0.01 and 0.001, respectively.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A formula for estimating creatinine clearance (CLCr) based on age, weight, serum creatinine levels, and gender adjustment. The equation includes factors for age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplier of 0.85 for female patients.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxyl group (CH2CO2H). The diagram illustrates the molecular formula arrangement of the drug's active ingredient.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

A scatter plot comparing difference percentages against daily doses (mg) from three studies (Study a, Study b, and Study c). The x-axis represents daily dose ranging from 600 to 1800 mg, and the y-axis represents difference percentage from 2% to 22%. Data points are marked with different colored squares corresponding to each study.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.